News | January 04, 2026
Elanco scores USDA nod for new canine allergy drug Befrena
Elanco expects Befrena to launch in the US in the first half of 2026
Elanco expects Befrena to launch in the US in the first half of 2026
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Subscribe To Our Newsletter & Stay Updated
